| | Characteristic | Total (N = 105) | Zercepac (n = 65) | Reference trastuzumab (n = 40) | P |
| | Age, years, mean ± SD | 48.73 ± 9.11 | 48.48 ± 9.28 | 49.15 ± 8.93 | 0.715 |
| | Sex, n (%) | | | | | | Female | 105 (100.0) | 65 (100.0) | 40 (100.0) | | | Male | 0 | 0 | 0 | |
| | BMI, kg/m2, median (range) | 23.20 (19.40, 26.50) | 22.40 (19.40, 26.50) | 23.40 (19.62, 26.47) | 0.877 |
| | Menstruation situation, n (%) | | | | 0.658 | | Premenopausal | 47 (44.8) | 28 (43.1) | 19 (47.5) | | | Postmenopausal | 58 (55.2) | 37 (56.9) | 21 (52.5) | |
| | Histological typing, n (%) | | | | | | Invasive carcinoma | 105 (100.0) | 65 (100.0) | 40 (100.0) | | | Other | 0 | 0 | 0 | |
| | Histological grading, n (%) | | | | 0.060 | | Grade 1 | 5 (4.8) | 3 (4.6) | 2 (5.0) | | | Grade 2 | 35 (33.3) | 27 (41.5) | 8 (20.0) | | | Grade 3 | 65 (61.9) | 35 (53.8) | 30 (75.0) | |
| | Time from diagnosis to trastuzumab treatment, days, media (range) | 6 (4, 9) | 6 (4, 12) | 6 (4, 8) | 0.691 |
| | HER2 status, n (%) | | | | | | - | 0 | 0 | 0 | | | + | 105 (100.0) | 65 (100.0) | 40 (100.0) | |
| | ER status, n (%) | | | | 0.728 | | - | 45 (42.9) | 27 (41.5) | 18 (45.0) | | | + | 60 (57.1) | 38 (58.5) | 22 (55.0) | |
| | PR status, n (%) | | | | 0.059 | | - | 67 (63.8) | 46 (70.8) | 21 (52.5) | | | + | 38 (36.2) | 19 (29.2) | 19 (47.5) | |
| | Molecular typing, n (%) | | | | 0.799 | | HER2+HR- | 41 (39.0) | 26 (40.0) | 15 (37.5) | | | HER2+HR+ | 64 (61.0) | 39 (60.0) | 25 (62.5) | |
| | Ki67, %, median (range) | 40.00 (40.00, 60.00) | 50.00 (40.00, 60.00) | 40.00 (30.00, 50.00) | 0.026 | | Maximum tumor diameter, mm, median (range) | 24.00 (18.00, 33.00) | 24.00 (18.00, 34.00) | 22.00 (18.75, 32.00) | 0.815 | | NLR, median (range) | 2.67 (1.78, 3.56) | 2.57 (1.88, 3.56) | 2.72 (1.64, 3.48) | 0.779 | | PLR, median (range) | 179.41 (137.73, 219.43) | 174.61 (137.28, 218.39) | 191.96 (139.06, 228.33) | 0.409 |
|
|
